Roche Holding AG RHHBF
485.00 USD +5.58 (+1.16%)
Regular-session close
485.00 Day range 485.00
375.00 52-week range 514.08
- YTD
- +8.84%
- 1 year
- +20.50%
News
zacks.com Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
zacks.com RHHBY Secures FDA Approval for Breast Cancer Treatment Roche wins FDA approval for Wilserdly plus everolimus, offering an all-oral treatment option for advanced breast cancer and strengthening its oncology portfolio.
wsj.com Roche Secures First U.S. Approval for New Breast-Cancer Pill The green light from the Food and Drug Administration marks the first approval for what Roche says could become the company's top-selling product.
businesswire.com FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Wilserdly (giredestrant) is now FDA-approved for ER+, ESR1-mutated advanced breast cancer, offering a new option to help delay disease…
globenewswire.com FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer Basel, 16 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination…
reuters.com US FDA approves Roche's oral treatment for advanced breast cancer US FDA approves Roche's oral treatment for advanced breast cancer
prnewswire.com Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories FDA De Novo authorization for the cobas® pro i 601 platform with Ionify® Gabapentin assay expands Roche's mass spectrometry menu into therapeutic drug monitoring. Designed to simplify traditionally…
